LAUNCH OF FIRST CELLS-ON-CHIP

AlveoliX AG introduces the revolutionary AX12C iAlv

Bern, Switzerland – June 26, 2023



AlveoliX AG is delighted to announce the highly anticipated release of their groundbreaking product, the AX12C iAlv (Cells-on-Chip). Featuring a primary human-derived alveolar epithelial cell line directly integrated onto the AX12 chip, the AX12C iAlv represents a significant advancement in lung-on-chip applications. These cells are specially optimized for long-term barrier formation and tight junctions, while also expressing alveolar epithelial and type 1 markers and alveolar epithelial type 2 markers.



Key features of AX12C iAlv:

- The AX12C iAlv offers researchers a ready-to-use alveolar epithelial barrier on-chip, enabling immediate experimentation.
- The integrated alveolar epithelial cell line is well characterized for toxicity and efficacy studies on-chip.
- The AX12C iAlv kit includes the appropriate cell culture medium, ensuring optimal growth and functionality of the alveolar cells, providing researchers with a seamless user experience.

Prominent institutions and companies served as beta testers for the AX12C iAlv:

> "The AX12C iAlv has opened up new avenues in disease modeling research. This technology has advanced our knowledge of host-pathogen interactions and demonstrated to be highly valuable in our recent studies on fungal infection dynamics, paving the way for novel approaches in combating respiratory fungal diseases."Stated Niki Ubags, Privat-docent and Responsable de Recherche at Centre Hospitalier Universitaire Vaudois (CHUV)

AlveoliX AG recognizes the global demand for accessible in-vitro solutions. Therefore, the AX12C iAlv will be available for worldwide shipping starting today.

About AlveoliX

AlveoliX's mission is to make organs-on-chips the new standard for preclinical decision-making and the leading alternative to animal experiments. For more information, visit www.alveolix.com or contact us at info@alveolix.com.